Back to List View Graph View

Mechanistic target of rapamycin (mTOR)

The Mechanistic target of rapamycin kinase (Mtor) is a central serine/threonine kinase that integrates growth factor, nutrient, energy, and stress signals to regulate cell growth, metabolism, protein synthesis, autophagy, and survival.

Where the papers sit

19 papers from the last 6 months study Mechanistic target of rapamycin (mTOR) directly · updated from PubMed 12 Nov 2026

Study type 0 clinical trials · 2 observational · 2 human data · 13 preclinical · 2 unclassified

Themes 4 themes

  • mTOR-Targeted Disease Therapy

    mTOR inhibition is being explored across lung and breast cancers, lymphangioleiomyomatosis, and post-transplant malignancy prevention. Sirolimus and everolimus recur alongside approaches intended to improve delivery or overcome resistance. ROS-linked apoptosis and glutamine dependence, including combined mTOR–GLS1 blockade, provide recurring mechanistic targets. The evidence remains disease-specific rather than establishing one treatment strategy.

    5 papers · 26.3%

  • AMPK-mTOR and Autophagy

    AMPK-mTOR control of autophagy and mitophagy is being pursued as a route to repair metabolic and degenerative tissue injury. Urolithin A improves cardiac remodeling through mitophagy, while macrophage autophagy supports diabetic foot healing. Metformin, butyrate, and pathway-focused interventions extend the work toward neuropathy and amyloid transport, but clinical evidence remains limited. Restoring autophagic flux, rather than simply inhibiting mTOR, is the recurring therapeutic aim.

    5 papers · 26.3%

  • Others — mTOR-Linked Disease Signaling

    mTOR-linked signaling recurs in inflammation, fibrosis, neuronal injury, and tumor behavior across otherwise distinct diseases. TSC1/miR-331-3p, NFκB, CCR5hi monocytes, and TIGIT/CD155 represent separate regulatory contexts. Autophagy and apoptosis are common endpoints, but the proposed mechanisms and tissues differ substantially. No unified therapeutic direction emerges from this heterogeneous set.

    6 papers · 31.6%

  • Others — mTOR Therapeutics Across Diseases

    mTOR dysregulation is linked separately to plaque lipophagy, gastric-cancer resistance to PD-1 blockade, and feline hypertrophic cardiomyopathy. The proposed axes include NPC2-mediated lipid handling and ITGA2-mTOR-CTSV signaling. Evidence ranges from multi-omics analysis to in silico inhibitor discovery, with no shared therapeutic regimen. These studies mainly define disease-specific targets rather than a common treatment direction.

    3 papers · 15.8%

Papers

The 19 papers from the last 6 months that study Mechanistic target of rapamycin (mTOR) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

mTOR-Targeted Disease Therapy (5)
  1. Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung · 5 Oct 2026 PMID 42832099
  2. A derivative of cytisine N-isoflavone from Sophora alopecuroides L., suppresses non-small cell lung cancer by targeting mTOR. European journal of pharmacology · 17 Jul 2026 PMID 42468678
  3. Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world data. JHEP reports : innovation in hepatology · 7 Jul 2026 PMID 42413767
  4. Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer. Pharmacological research · 11 Jun 2026 PMID 42276398
  5. Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
AMPK-mTOR and Autophagy (5)
  1. Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
  2. Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis to ameliorate cardiac remodeling in HFpEF. Experimental & molecular medicine · 10 Jul 2026 PMID 42432192
  3. Molecular mechanisms of autophagy disorder in diabetic neuropathy: Focusing on signaling pathways and regulation of lipid metabolism. PloS one · 9 Jul 2026 PMID 42424320
  4. Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
  5. Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
Others — mTOR-Linked Disease Signaling (6)
  1. Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
  2. Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis. Apoptosis : an international journal on programmed cell death · 27 Jul 2026 PMID 42507162
  3. An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups. Endocrine pathology · 9 Jul 2026 PMID 42424015
  4. Exosomes from diabetic perirenal adipose-derived MSCs promote inflammation and fibrosis in diabetic nephropathy via the miR-331-3p/TSC1/mTORC1 Axis. International immunopharmacology · 8 Jul 2026 PMID 42419147
  5. SMN haploinsufficiency exacerbates high glucose dialysate-induced peritoneal inflammation and fibrosis via mTOR/NFκB signaling pathway. Biochimica et biophysica acta. Molecular cell research · 19 Jun 2026 PMID 42320860
  6. Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. Journal of molecular histology · 21 May 2026 PMID 42165939
Others — mTOR Therapeutics Across Diseases (3)
  1. A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
  2. Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. Journal for immunotherapy of cancer · 6 Aug 2026 PMID 42562425
  3. In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166

By study type

Observational studies and case reports (2)
  1. Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung · 5 Oct 2026 PMID 42832099
  2. Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world data. JHEP reports : innovation in hepatology · 7 Jul 2026 PMID 42413767
Human data, design not indexed (2)
  1. Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
  2. An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups. Endocrine pathology · 9 Jul 2026 PMID 42424015
Preclinical: animal, cell and lab studies (13)
  1. Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
  2. Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. Journal for immunotherapy of cancer · 6 Aug 2026 PMID 42562425
  3. Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis. Apoptosis : an international journal on programmed cell death · 27 Jul 2026 PMID 42507162
  4. A derivative of cytisine N-isoflavone from Sophora alopecuroides L., suppresses non-small cell lung cancer by targeting mTOR. European journal of pharmacology · 17 Jul 2026 PMID 42468678
  5. Molecular mechanisms of autophagy disorder in diabetic neuropathy: Focusing on signaling pathways and regulation of lipid metabolism. PloS one · 9 Jul 2026 PMID 42424320
  6. Exosomes from diabetic perirenal adipose-derived MSCs promote inflammation and fibrosis in diabetic nephropathy via the miR-331-3p/TSC1/mTORC1 Axis. International immunopharmacology · 8 Jul 2026 PMID 42419147
  7. Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
  8. In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166
  9. SMN haploinsufficiency exacerbates high glucose dialysate-induced peritoneal inflammation and fibrosis via mTOR/NFκB signaling pathway. Biochimica et biophysica acta. Molecular cell research · 19 Jun 2026 PMID 42320860
  10. Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer. Pharmacological research · 11 Jun 2026 PMID 42276398
  11. Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
  12. Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
  13. Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. Journal of molecular histology · 21 May 2026 PMID 42165939
Unclassified: not yet indexed with MeSH (2)
  1. A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
  2. Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis to ameliorate cardiac remodeling in HFpEF. Experimental & molecular medicine · 10 Jul 2026 PMID 42432192